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[57] ABSTRACT 
A kit and method of non-destructively radiolabelling a 
biomolecule substrate by halogenation, including the 
steps of: a) reacting a secondary amine with a chlorinat 
ing agent to produce an N-chloro secondary amine, (b) 
reacting the N-chloro secondary amine with a salt of a 
radiolabelled halogen to produce a radiolabelled halo 
genating agent, (0) reacting a solution of the biomole 
cule substrate with the radiolabelled halogenating 
agent, and (d) recovering a radiohalogenated biomole 
cule from the reaction of step (c). The kit and method 
allow for more complete iodination with a lessening of 
side reactions such as decomposition of the biomolecule 
substrate to be labelled. 
22 Claims, 3 Drawing Sheets 
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NON-DESTRUCT IVE METHOD FOR 
RADIOLABELLING BIOMOLECULES BY 
HALOGENATION 
TECHNICAL FIELD 
The present invention relates to a non-destructive 
method for radiolabelling biomolecules by halogena 
tion. The method for halogenating or iodinating chemi 
cally sensitive substrates of the invention employs a 
secondary amine to reduce the oxidation potential of 
chloramine-T (sodium-p-toluene sulfo-chloramine or 
CAT) or other chlorinating agent. The present inven 
tion has been found to produce more complete haloge 
nation or iodination with less side reaction than the 
traditional methods in which CAT is bonded to poly 
mer beads. The method may be commercialized in kit 
form. 
BACKGROUND ART 
Frequently, it is desirable to radiolabel bioactive mol 
ecules with radioactive iodine or other halogens such as 
bromine. Most commonly, radioactive iodine is sup 
plied in the form of KI* (wherein * represents a radioi 
sotope of the halogen of interest, e.g., I125 or I131), and 
the labeling procedure involves reaction of KI* with 
chloramine-T (CAT) to release I;* followed by addi 
tion of the substrate which then takes up the 12* to form 
a radioiodinated product. 
A major drawback to this procedure occurs when the 
substrate (compound to be labeled) is sensitive to oxida 
tion or chlorination. Poor yields of 'the desired radi 
ohalogenated or radioiodinated product and possibly 
complete decomposition of the substrate may occur 
through oxidation or chlorination, if residual CAT is 
left in the solution when the substrate is added. 
The IODOBEADS ® system (Pearce Chemical 
Company) attempts to avoid the problem of substrate 
decomposition by bonding the CAT onto polymer 
beads. A KI* solution is added to the beads and shaken 
to release free 1*;. A solution of the substrate is then 
added and shaken until the brown color disappears, 
then the beads are immediately ?ltered off to remove 
any residual CAT. The radioiodinated product is sepa 
rated from the solution by preparative HPLC. 
This system is only partially successful because CAT 
is released from the beads very rapidly. With sensitive 
substrates, if the manipulations are not carried out very 
quickly, signi?cant amounts of CAT will appear in the 
solution and decompose the substrate. In many cases, 
the yields are very poor even though the procedure is 
carried out as quickly as possible. Finally, preparation 
of the polymer beads is relatively expensive. 
Methods are known for radioiodinating molecules 
using chloramine-T (sodium-p-toluenesulfochlora 
mine). 
U.S. Pat. No. 3,867,518 to Coffey et al. describes a 
radioimmunoassay for insulin and further describes a 
method for the preparation of radioiodinated insulin 
using chloramine-T (sodium-p-toluenesulfochloramine) 
and a phosphate buffer. Coffey et al. does not disclose 
or suggest the use of piperidine or N-chloro-piperidine 
in a method of radioiodination. 
U.S. Pat. No. 4,196,185 to Focella discloses an immu~ 
noassay for phencyclidine. To prepare radioiodinated 
N-(4-hydroxy-2-phenelthyl)-4-[l-piperidinyl)cy 
clohexyl] benzene acid sulfate, the compound was 
placed in ethyl acetate and water was added to a vial 
5,424,402 
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containing Na125l. To this mixture was added chlora 
mine-T. Then sodium meta bisul?te was added to stop 
the reaction. 
U.S. Pat. No. 4,436,718 to Smith discloses an iodinat 
ing reagent. This patent discloses that N-chloro~4 
methylbenzenesulfonamide or chloramine-T has long 
been used as the oxidant to mediate iodination reactions. 
The disclosure states that the use of chloramine-T has 
its drawbacks. The oxidant of Smith comprises a water 
insoluble bead having covalently attached to its surface 
molecules a chloramine group, with a size and shape of 
the bead being compatible with easy physical separation 
of the oxidant from a solution of the biological speci 
men. In the invention of Smith, chlorosulfonic acid, 
aqueous ammonia, and sodium hypochlorite yield the 
most preferred N-chlorobenzene sulfonamide function 
ality on the beads. 
U.S. Pat. No. 4,450,149 to Kabalka et al. discloses a 
radiohalogenation method. In the method of Kabalka, 
the general procedure for iodination involved adding 
methanol and organoborane. Iodine-mono-chloride is 
then added. Sodium thiosulfate is then added to the 
mixture and the layers are dried over magnesium sul?te. 
Benzoyl chloride was added to 4-penten-l-ol in pyridine 
and stirred overnight at room temperature. Sequen 
tially, diluted HCl was added and the mixture was satu 
rated with aqueous Na2CO3 and water. 
U.S. Pat. No. 4,528,134 to Stentz et al. discloses a 
method of iodinating insulin using chloramine-T. U.S. 
Pat. No. 4,591,552 to Neurath discloses the detection of 
hepatitis B surface antigen with labelled synthetic pep 
tide. This patent discloses that if a peptide contains 
tyrosine it can be labelled by contacting the peptide 
with sodium I125 in a buffer and then oxidizing it in the 
presence of chloramine-T. Neurath discloses that the 
peptide can be labelled with or without a solid support 
such as polystyrene beads. U.S. Pat. No. 4,775,638 to 
Haisma discloses a single vial technique for radiolabell 
ing protein. Haisma discloses use of coupling agents 
such as iodogen (1,3,4,6-tetrachloro-3,6-diphenyl 
glycuril), chloramine-T, lactoperoxidase and iodine 
monochloride. Iodination is conducted on an ion ex 
change resin. 
U.S. Pat. No. 4,874,601 to Flanagan discloses a radi~ 
olabelling kit. The radiolabelling kit of Flanagan in 
cludes oxidizing agents such the sodium salt of N 
chloro-p-toluenesolufonamide or chloramine-T, iodo 
gen, or iodobeads (chloramine-T bonded to polystyrene 
beads). Flanagan does not disclose or suggest the use of 
piperidine or N-chloro-piperidine in a method of radioi 
odination. 
U.S. Pat. No. 4,966,999 to Coughlin et al. discloses 
radiohalogenated compounds for site speci?c labelling. 
The process of Coughlin et al. includes an oxidant such 
as chloramine-T, iodobeads or iodogen. Coughlin does 
not disclose or suggest the use of piperidine or N 
chloro-piperidine in a method of radioiodination. 
U.S. Pat. No. 4,994,258 to Burns et al. discloses novel 
radiolabelled antagonists for pancreatic imaging. The 
radiolabelling process takes place in a sodium hydrox 
ide solution of Na125I in the presence of cupric sulfate 
and ammonium sulfate. 
U.S. Pat. No. 5,084,266 to McKenzie et al. discloses a 
method for tumor imaging utilizing a labelled tumor 
speci?c antibody and a non-tumor reactive antibody. 
McKenzie et al. found that the chloramine-T method 
for radiolabelling resulted in a greater loss of immuno 
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reactivity than either the iodobead or enzymobead 
method. The enzymobead method was the method of 
choice for labelling in the method of McKenzie et al. 
US. Pat. No. 5,171,666 to Gutowski et al. discloses 
the labelling of immunoglobulins using chloramine-T. 
The publication of Markussen, J. et al., Insulin: 
Chem, Struc. Funct. Insulin Relat. H0rm., Proc. Inzt, 
Insulin Symp. (1980) pp. 16l—l68 is entitled “The Appli 
cation of HPLC to the Analysis of Radioiodinated 
Tracers of Glucagon and Insulin”. This publication 
discloses the use of chloramine T and lactoperoxidase in 
the radioiodination of glucagon. 
The publication of Boothe, Thomas E. et al., J. La 
belled Compd. Radiopharm, Vol. 23, (1986) pp. 
479-485, entitled “The Preparation of No-carrier 
Added 4-[131I] iodoantipyrine using chloramine-T. The 
publication discloses the use of chloramine-T and iodo 
gen to iodinate antipyrine for use as a tracer in studying 
cerebral blood flow. 
Dickinson, Kenneth E., et al., M01. PharmacoL, Vol. 
26, No. 2, (1984) pp. l87—l95. “Photoaf?nity Crosslink 
ing of a Radioiodinated Probe 125I-A55453, into Alpha 
l-Adrenergic Receptors” discloses the radioiodina 
tion of an alphal-adrenergic receptor probe. The 
method of radioiodination includes the use of chlora 
mine-T and Na125I. 
Youfeng, He, et al., J. Labelled Compd. Radiopharm, 
Vol. 19, (1982) pp. 807-819, “A Comparative Study of 
Radioiodination of Simple Aromatic Compounds via 
N-Halo-Succinimides and chloramine-T in Trifluoro 
acetic Anhydride (TFAA)”. This paper reports the 
comparative results of radioiodination performed using 
N-chlorotetratluorosuccinimide, N-chlorosuccinimide, 
N-bromosuccinimide, and chloramine-T (CAT) as oxi 
dizing agents with TFAA as an aprotic solvent. The 
study concluded that CAT is a superior oxidizing agent 
for the iodination of simple benzenes which are water 
insoluble but which are soluble in TFAA. 
Nakamura, Masahiro, et al., Radioisoptopes, Vol. 40, 
No. 3, (1991) pp. 112-117, “Preparation and Evaluation 
of Radio Labelled Recombinant Human Interleukin-2 
by Improved Chloramine-T Method”. This publication 
discloses the use of a very small quantity of chloramine 
T to activate iodine (21 fold excess to iodine in molar 
ratio). This method of iododination is useful for iodin 
ation of unstable peptides and proteins. 
Baindur, Nandkishore, eta1., J. Med. Chem, Vol. 31, 
No. 11, (1988) pp. 2069-2071, “Discloses a Photoaf 
?nity Label for the D-1 Dopamine Receptor”. Radioi 
odination methodology used by Baidur includes the use 
of a modi?ed NaI-Chloramine-T procedure. None of 
the above patents or publications disclose or suggest the 
use of piperidine or N-chloro-piperidine in a method of 
radioiodination. 
The method of radiohalogenation of the present in 
vention overcomes the de?ciencies of prior art methods 
and provides an inexpensive method for radi 
ohalogenating biomolecules which is non-destructive to 
the biomolecule. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a comparison of two methods of iodin 
ation of a Glysine-Tyrosine (Gly-Tyr) and an NAD 
analog using CAT—Example l and CAT+dimethyla 
mine (DMA)—Example 2. 
FIG. 2 shows the influence of incubation of the sub 
strate-iodide-CAT (Example la) mixture or the sub 
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strate-iodide-CAT-DMA mixture (Example 2a) on the 
production of desired and side products for Gly-Try. 
FIG. 3 shows the in?uence of time of preincubation 
of the CAT-DMA mixture before the introduction into 
the substrate iodine mixture on the production of the 
desired product for Gly-Tyr. 
FIG. 4 shows the in?uence of the DMA/CAT ratio 
on the production of the desired product for Gly-Tyr. 
FIG. 5 shows the iodination of Gly-Tyr by three 
methods employing Iodobeads ®. 
FIG. 6 shows a comparison of Example 2a 
(CAT+DMA solution) with Example 4 
(Iodobeads ®+DMA) for iodination of Gly-Tyr. 
DISCLOSURE OF THE INVENTION 
The present invention provides a method of nonde 
structively radiolabelling a biomolecule substrate by 
halogenation, comprising the steps of: 
(a) reacting a secondary amine with a chlorinating 
agent to produce an N-chloro secondary amine, 
(b) reacting said N-chloro secondary amine with a 
salt of a radiolabelled halogen to produce a radi 
olabelled halogenating agent, 
(0) reacting a solution of said biomolecule substrate 
with said radiolabelled halogenating agent, and 
(d) recovering a radiohalogenated biomolecule from 
the reaction of step (c). 
The invention also provides a method of producing a 
radiolabelled halogenating agent for non-destructively 
radiolabelling a substrate by halogenation, comprising 
the steps of: 
(a) reacting a secondary amine with a chlorinating 
agent to produce an N-chloro secondary amine, and 
(b) reacting said N-chloro secondary amine with the 
salt of a radiolabelled halogen to produce a radi 
olabelled halogenating agent. 
Additionally the invention provides a method of non 
destructively radiolabelling a biomolecule substrate by 
radioiodination, comprising the steps of: 
(a) mixing dry chloramine-T powder or chloramine 
T bonded to polymer beads, with a solution of a second~ 
ary amine to reduce the oxidation potential of chlora 
mine-T, to form a mixture, 
(b) shaking said mixture until all the chloramine-T 
powder has dissolved, 
(0) adding a solution of KI* or NaI* to said mixture, 
wherein 1* represents a radioisotope of iodine, 
(d) shaking said mixture of step (c) for a time suffi 
cient to release 12* in solution, 
(e) adding a solution of said biomolecule substrate to 
said mixture, 
(f) shaking the resulting mixture of step (e) until the 
brown color disappears, and 
(g) recovering the radioiodinated biomolecule. 
Advantageously, the invention provides a kit for 
non-destructively radiolabelling biomolecules by halo 
genation, comprising 
(a) a vial comprising a chlorinating agent, and 
(b) a vial comprising a solution of a secondary amine, 
(c) instructions for use. 
The kit, preferably, further comprises a vial compris 
ing a solution a salt of a radiolabelled halogen. 
Also provided for is a method of non-destructively 
radiolabelling a biomolecule substrate by halogenation, 
comprising the steps of: 
(a) mixing dry chloramine-T powder or chloramine 
T bonded to polymer beads, with a solution of a second 
ary amine in molar excess over said chloramine-T pow 
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der or chloramine-T bonded to polymer beads, to form 
a mixture, 
(b) shaking said mixture until all the chloramine-T 
powder has dissolved, 
(c) adding a solution of KX* or NaX* to said mixture, 
wherein X* is a radioisotope of a halogen, 
(d) shaking said mixture of step (c) for a time suffi 
cient to release X* in solution, 
(e) adding a solution of said biomolecule substrate to 
said mixture, 
(1) shaking the resulting mixture of step (e) until the 
color disappears, and I 
(g) recovering the radiohalogenated biomolecule. 
The radioactive iodide is preferably selected from 
1211 or 1351 and radioactive bromide is preferably 77Br. 
It is preferred that the chloramine-T is in molar excess 
over KX* or NaX*, X* is a radioisotope of a halogen. 
DESCRIPTION OF THE INVENTION 
The invention provides a method of radiolabelling 
bioactive molecules with radioactive iodine or other 
radioactive halogens such as bromide. Radioactive io 
dide or bromide are preferred. Examples of radioactive 
iodide include 1251 and 1311. An example of radioactive 
bromide is 77Br. 
Bioactive molecule substrates which may be radi 
olabelled according to the method of the invention, 
include but are not limited to amino acids, peptides, 
proteins, drug molecules, antibodies, probes and diag 
nostic reagents. 
The bioactive molecule substrates can be used in any 
process which requires a radiolabelled molecule. For 
example, such bioactive molecule substrates can be used 
in radioimmunoassays, enzyme-immunoassays, and for 
radiolabelling compounds to determine their location 
and/or distribution in animals, including humans. 
Certain N-chloroamines have relatively low chlorine 
potentials, that is, they are relatively poor chlorinating 
and oxidizing agents. For example, N-chloro-piperidine 
(N-Cl-PIP) has a chlorine potential of 0.05, whereas 
CAT has a chlorine potential greater than 1. N-Cl~PIP 
is a much weaker oxidizing/chlorinating agent than 
CAT. N-Cl-PIP rapidly and quantitatively releases I; 
from I" in solution. This release is so facile that the 
active chlorine in N-Cl-PIP can be titrated iodometri 
cally. 
Thus, N-Cl-PIP could be used to release 1*; from I*— 
for radioiodination procedures. Unfortunately, N-Cl 
PIP is not sufficiently stable either in aqueous solution 
or in its pure state to be packaged and sold commer 
cially. ‘ 
On the other hand, secondary amines, preferably 
dialkyl amines including but not limited to diisopropyl 
amine, dibutylamine, dimethylamine, morpholine, me 
thylethylamine, 2-(N)-methylamino heptane, N 
isobutylamine, ethyl-n-butylamine, methyl-sec-butyla 
mine, and piperidine (PIP), react rapidly and quantita 
tively with CAT to form N-chloro-secondary amines in 
solution. Any secondary amine may be used to practice 
the invention, and thus the invention need not be limited 
to the use of dialkylamines. For example, piperidine 
(PIP) reacts rapidly and quantitatively with CAT to 
form N-Cl-PIP in solution, as follows: 
PIP + CAT = N-Cl-PIP + p-toluenesulfonarnide 
TSA). 
In a preferred embodiment, when the pH is in the 
range of 3 to 10, this reaction is complete inabout 30 
seconds or less. Since CAT is stable in the dry state, it 
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can be used to produce N-Cl-PIP in situ immediately 
prior to use in the radiolabelling method of the inven 
tion. 
Thus, present invention provides a method of nonde 
structively radiolabelling a biomolecule substrate by 
halogenation, comprising the steps of: 
(a) reacting a secondary amine with a chlorinating 
agent to produce an N-chloro secondary amine, 
(b) reacting said N-chloro secondary amine with a 
salt of a radiolabelled halogen to produce a radi 
olabelled halogenating agent, 
(c) reacting a solution of said biomolecule substrate 
with said radiolabelled halogenating agent, and 
(d) recovering a radiohalogenated biomolecule from 
the reaction of step (c). 
The radio-halogenated biomolecule may preferably 
be recovered by preparative high pressure liquid chro~ 
matography. The secondary amine may be selected 
from dialkylamines, selected from dimethyl amine, di 
ethylamine, diisopropylamine, dibutylamine morpho 
line and piperidine (PIP). 
A cation of the salt of the radiolabelled halogen may 
be selected from the group consisting of sodium, potas 
sium, lithium, rubidium, cesium, magnesium, calcium 
and ammonium. 
The chlorinating agent may be selected from chlora 
mine-T, chloramine-T bonded to polymer beads, hala 
zone, N-chlorosuccinimide, tetrachloroglycoluril, so 
dium hypochlorite, hypochlorus acid and elemental 
chlorine. 
The bioactive molecule substrate may include amino 
acids, peptides, proteins, drug molecules, drug metabo 
lites, antibodies, probes and diagnostic reagents. 
The present invention provides a method for non 
destructively radiolabelling a biomolecule substrate by 
halogenation, including steps of: (a) mixing dry chlora 
mine-T powder or chloramine-T bonded to polymer 
beads, with a solution of a secondary amine in molar 
excess over chloramine~T powder, to form a mixture, 
(b) shaking the mixture until all the chloramine-T pow 
der has dissolved, (c) adding a solution of KX* or NaX* 
to the mixture, wherein X* is a radioisotope of a halo 
gen, (d) shaking the mixture of step (c) for a time suf? 
cient to release X* in solution which preferably is about 
30 seconds, (e) adding a solution of the biomolecule 
substrate to said mixture, (f) shaking the resulting mix 
ture of step (e) until the color disappears, and (g) recov 
ering the radiohalogenated biomolecule. 
In an alternative embodiment, the invention provides 
a method for non-destructively radiolabelling a biomol 
ecule substrate by radioiodination, comprising the steps 
Of: 
(a) mixing dry chloramine-T powder or chloramine 
T bonded to polymer beads, with a solution of a second 
ary amine to reduce the oxidation potential of chlora 
mine-T, to form a mixture, 
(b) shaking the mixture until all the chloramine-T 
powder has dissolved, 
(0) adding a solution of KI* or NaI* to the mixture, 
(d) shaking the mixture of step (c) for a time suf?cient 
to release 1* in solution which preferably is about 30 
seconds, 
(e) adding a solution of the biomolecule substrate to 
said mixture, 
(f) shaking the resulting mixture of step (e) until the 
brown color disappears, and 
(g) recovering the radioiodinated biomolecule. 
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Dry chloramine-T powder or chloramine-T bonded 
to polymer beads may be mixed with the secondary 
amine in step (a). It is also preferred that the secondary 
amine is piperidine (PIP) buffered at about pH 6.0 in 
molar excess over chloramine-T powder. 
Advantageously, the invention provides a kit for 
non-destructively radiolabelling biomolecules by halo 
genation, comprising (a) a vial comprising a solution of 
KI* or NaI*, and (b) a vial comprising dry chloramine~ 
T powder or chloramine-T bonded to polymer beads in 
molar excess over KI*, (c) a vial comprising a solution 
of a secondary amine in molar excess over chloramine 
T powder, (d) instructions for use. 
Thus, the present invention provides for a kit for 
radioiodination of biomolecules. The kit preferably 
consists of two vials. Vial 1 contains a chlorinating 
agent such as dry CAT powder or the CAT bonded to 
polymer beads, and Vial 2 contains a solution of a sec 
ondary amine which is preferably, PIP buffered at pH 
6.0. To radioiodinate a substrate, Vial 2 is added to Vial 
l and shaken until all the CAT particles have dissolved. 
KI* is then added and the mixture shaken for about 30 
seconds or a time suf?cient to release 12* in solution. 
A solution of the substrate, is then added and the 
mixture shaken until the color, brown color in the case 
of iodine, disappears. The radioiodinated product may 
be recovered by preparative HPLC in the manner 
known in the art. 
After mixing Vial l and Vial 2, it is preferred to en 
sure that all CAT particles are dissolved before the 
substrate is added. 
The kit should contain a secondary amine, such as 
PIP, in molar excess over CAT to ensure complete 
decomposition of the CAT before the substrate is 
added. CAT should be present in molar excess over KI* 
to ensure complete conversion of I*— to I*2. 
According to the method of the invention it would 
not be necessary to hurry any step of this procedure 
since 1*; is relatively stable in solution and any reaction 
between residual N-Cl-PIP (or other chlorinated sec 
ondary amine) and the radioiodinated product would 
occur very slowly, if at all. 
In a preferred embodiment the KI* is included in Vial 
2, however, it may also‘ be added separately from a third 
vial by the researcher during the procedure. 
Below is a flow chart depicting an example of the 
radiohalogenation method of the invention. Radioio 
dine is used as an example. The molar quantities indi 
cated below are intended to show ratios and are in 
cluded for illustration only. 
TYPICAL FLOW CHART FOR RADIOHALOGENATION 
' METHOD 
1. Vial l - CAT (dry powder 2 mmol) + Vial 2 - Aqueous 
solution buffered at pH 6.0 containing PIP 3 mmol. 
2. Mix and shake until ALL CAT PARTICLES are dissolved. 
3. Add - KI* 1 mmol 
Substrate 2 mmol 
4. Mix and stand for about 30 seconds. 
VIAL CONTENTS 
Vial l - Aqueous solution containing 
P-TSA 2 mmol 
I*-Substrate (labeled) 1 mmol 
Substrate (unlabeled) 1 mmol 
Treat with Sodium 
Thiosulfate 
5. Preparative HPLC to recover labeled substrate 
6. Results in I*-Substrate (labeled) 1 mmol. 
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Several iodination experiments were run with various 
modi?cations of both the new non-destructive method 
as compared to a method using CAT bonded to poly 
mer beads. The dipeptide, glycine-tyrosine (Gly-Tyr), 
and a nicotinamide adenine dinucleotide (NAD) analog 
were chosen as model substrates. The results show that, 
under optimum conditions, the method of the present 
invention resulted in up to 4 times more iodine being 
taken up by the substrate compared with methods em 
ploying CAT bonded to polymer beads. In the case of 
Gly-Tyr, the new method produced signi?cantly less 
side reaction product. 
Details of the methods and the exact compositions of 
. the solutions are given at the end of this section. The 
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results are shown as bar charts of counts per minute 
scraped from the thin layer chromatography (TLC) 
plates used to separate the iodinated products from the 
other reaction products. 
DETAILED DESCRIPTION OF THE 
' DRAWINGS 
FIG. 1 shows that when CAT was used alone as the 
oxidizing agent (Method I, corresponding to the proce 
dure of Example 1), the degree of iodination of the two 
substrates was signi?cantly less than when dimethylam 
ine (DMA) was mixed with the CAT one minute before 
adding the substrate and iodide (Method II, Example 
II). FIG. 1 also shows that the amount of a side reaction 
product formed during the reaction with Gly-Tyr was 
signi?cantly reduced in the presence of DMA. 
FIG. 2 shows that incubating either the substrate 
iodide-CAT or the substrate-iodide-CAT-DMA system 
for longer than 30 seconds results in a lower yield of 
iodinated Gly-Tyr and a greater yield of side reaction 
product. 
FIG. 3 shows that preincubation of the CAT-DMA 
mixture for l, 2, or 3 minutes prior to adding the sub 
strate and iodide has no effect on the degree of iodin 
ation of Gly-Tyr. These results suggest that CAT trans 
fers all its chlorine to DMA in the ?rst few seconds 
after the substances are mixed. 
FIG. 4 shows that increasing the ratio of DMA to 
CAT from 1 to 5 does not influence the degree of iodin 
ation of Gly-Tyr. This also suggests that DMA/CAT 
ratios greater than 1 may not be needed to protect sub 
strates from decomposition. 
FIG. 5 shows the results of three methods employing 
Iodobeads® with Gly-Tyr. Method III, which em 
ployed Iodobeads ® alone, gave signi?cantly less iodi 
nated product than Methods IV and IVa which em 
ployed Iodobeads ®+DMA. 
FIG. 6 shows a comparison of Method IIa 
(CAT+DMA solution) with Method IV 
(Iodobeads ®+DMA). The results show that Method 
IIa gives approximately four-fold greater iodination 
than that given by Method IV. 
Note method numbers in the ?gures correspond to 
example numbers set forth below in the examples of the 
invention. 
EXAMPLES 
The examples set forth below correspond to the 
methods and their results indicated in the ?gures. 
COMPARATIVE EXAMPLE I (CAT Solution Only) 
5 ttl of Substrate (Gly-Tyr) Solution OR 
5 ul Substrate (NAD) Solution 
+5 ul NaI Carrier Solution 
5,424,402 
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+5 pl NaI Labeled Solution REMOVE 30 pl aliquot 
+10 pl CAT Solution RUN TLC (see Example I) 
STIR 30 seconds 7 
ADD 30 pl Sodium Thiosulfate Solution INVENTION EXAMPLE Iv (I°‘l°beadS ®+DMA 
REMOVE 30 “I aliquot 5 Example) (Glycine-Tyrosine only) 
RUN thin layer chromatography (TLC) Same procedures as Example III, except: 
For Glycine-Tyrosine: n-butanolzAcOHJIgO, 4:2:1 5 pl DMA Solution 
For NAD Analog: n-butanolzAcOHzHgo, 5:2:3 +30 pl 0.5M, pH 7.5 Phosphate Buffer was substi 
CUT BANDS from TLC tuted for 30 pl of buffer solution. 
DISPERSE in 10 ml water 10 
INVENTION EXAMPLE IVa (Iodobeads ®+DMA TRANSFER 2 l f l t t ' t'll t' . P’ O C ear Supema e o Scm l a Ion with Incubation Example) (Glycine-Tyrosine only) 
vials containing 10 ml Fischer Scintillation II liquid 
scintillation cocktail. Same procedures as Example IV, except: 
COUNT using a Packard Model 3375 Tri-Carb Liq- Two (2) Iodobeads ® 
uid Scintillation Spectrometer. 15 +5 pl DMA Solution 
+30 pl 0.5M, pH 7.5 Phosphate Buffer were incu 
bated for 1 minute at room temperature before 
being added to the substrate-iodide mixture. 
INVENTION EXAMPLE II (CAT+DMA Solution) 
(Glycine-Tyrosine only) 
Same procedures as Example I, except: 
10 pl CAT Solution was mixed with 10 p1 dimethyl~ 2o EXAMPLE SOLUTIONS 
amine (DMA) Solution and incubated 1 min at room Substrate Solution (Gly-Tyr)—l mg/ml Glycine 
temperature before being added to the substrate-iodide Tyrosine in 0.5M., pH 7.5 Phosphate Buffer. 
mixture. Substrate Solution (NAD)—1 mg/ml NAD analog in 
0.5M., pH 7.5 Phosphate Buffer. 
COMPARATIVE EXAMPLE Ia (CAT only) 25 NaI Carrier Solution—l.5 mg/ml NaI in 0.5M., pH 
(Glycme'Tyrosme) 7.5 Phosphate Buffer. 
Same procedures as Example I, except: The reaction NaI Labeled Solution-13,000 cpm/ pl of NaI125 in 
mixture consisting of substrate-iodide-CAT was incu- 0.005M., pH 7.5 Phosphate Buffer. 
bated 0.5, 3 or 6 minutes before adding the Sodium CAT Solution—5 mg/ml Chloramine-T in 0.05M., 
Thiosulfate Solution. 30 pH 7.5 Phosphate Buffer. 
. Sodium Thiosulfate Solution—5 mg/ml Na2S2O4 in 
INVENTION EXAMPLE IIa (CAT+DMA Solution 0.05M. pH 75 Phosphate Buffer. 
with Various Incubation Times) (Glycine-Tyrosine DMA S0lutiOn_2 mg/ml dimethylamine in 0_5M_ 
only) pH 7.5 Phosphate Buffer. 
Same proceduresasExample II, except: The reaction 35 The foregoing description of the speci?c embodi 
mixture consisting of substrate-iodide-CAT-DMA was ments will so fully reveal the general nature of the in 
incubated 0.5, 3 or 6 minutes before adding the Sodium vention that others can, by applying current knowl 
Thiosulfate Solution. edge, readily modify and/or adapt for various applica 
tions such speci?c embodiments without departing 
INVENTjION XAMPLE nb & .110 ICAT+DMA 40 from the generic concept and therefore such adapta 
Solutton with Various Incubation Times and . . . tions are intended to be comprehended within the 
DMA/CAT Ratios) (Glycme'Tyrosme only) meaning and range of equivalents of the disclosed em 
Same procedures as Example 11, except: bodiments. It is to be understood that the phraseology 
IIb-The DMA+CAT Mixture was incubated for l, or terminology employed herein is for the purpose of 
2, or 3 minutes before addition to the substrate-iodide 45 description only and not of limitation. It will be obvious 
mixture (reaction time=3O sec.). that certain changes and modi?cations may be practiced 
IIc-The ratio of DMA/CAT was either 1 or 5 (incu- within the scope of the appended claims. 
bation time=l min.; reaction time=30 sec.). We claim: 
1. A method of non-destructively radiolabelling a 
INVENTION EXAMPLE Hd & He (CAT+dialky1 5O biomolecule substrate by halogenation, comprising the 
amine Solution) steps of: 
Same procedures as Example II, except: (a) reacting a secondary amine with a chlorinating 
IId—Dibutylamine+CAT Mixture was incubated agent to produce an N-chloro secondary amine, 
for l, 2, or.3 minutes before addition to the substrate- (b) reacting said N-chloro secondary amine with a 
iodide mixture (reaction time=30 sec.). 55 radiolabelled halide salt to produce a radiolabelled 
IIe-Diisopropylamine+CAT Mixture was incu- elemental halogen, 
bated for 1, 2, or 3 minutes before addition to the sub- (c) reacting a solution of a biomolecule substrate with 
strate-iodide mixture (reaction time=30 sec.). said radiolabelled elemental halogen, wherein said 
radiolabelled elemental halogen reacts directly 
COMPARATIVE EXAMPLE In (Iodobeads ® 60 with said biomolecule substrate to produce a radi 
Example) (Glycine'Tyrosine only) ohalogenated biomolecule, and 
5 pl Substrate (Gly-Tyr) Solution (d) recovering a radiohalogenated biomolecule from 
+5 pl NaI Carrier Solution ' the reaction of step (c). 
+35p 0.5M, pH,75 Phosphate Buffer 2. The method of claim 1, wherein said radi 
+5 pl NaI Labeled Solution 65 ohalogenated biomolecule is recovered by preparative 
MIX high pressure liquid chromatography. 
ADD two (2) Iodobeads® 3. The method of claim 1, wherein said secondary 
STAND 1 minute amine is selected from dialkylamines. 
5,424,402 
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4. The method of claim 1, wherein said secondary 
amine is selected from the group consisting of dimethyl 
amine, diethylamine, diisopropylamine, dibutylamine, 
morpholine and piperidine (PIP). 
5. The method of claim 1, wherein the cation of said 
radiolabelled halide salt is selected from the group con 
sisting of sodium, potassium, lithium, rubidium, cesium, 
magnesium, calcium and ammonium. 
6. The method of claim 1, wherein said chlorinating 
agent is selected from the group consisting of chlora 
mine-T, chloramine-T bonded to polymer beads, hala 
zone, N-chlorosuccinimide, tetrachloroglycoluril, so 
dium hypochlorite, hypochlorus acid and elemental 
chlorine. 
7. The method of claim 1, wherein the biomolecule 
substrate is selected from the group consisting of amino 
acids, peptides, proteins, drug molecules, drug metabo 
lites, antibodies, probes and diagnostic reagents. 
8. A method of producing a radiolabelled halogenat 
ing agent for non-destructively radiolabelling a sub 
strate by halogenation, comprising the steps of: 
(a) reacting a secondary amine with a chlorinating 
agent to produce an N-chloro secondary amine, 
and 
(b) reacting said N-chloro secondary amine with the 
salt of a radiolabelled halogen to produce a radi 
olabelled halogenating agent. 
9. A method of non-destructively radiolabelling a 
biomolecule substrate by radioiodination, comprising 
the steps of: 
(a) mixing dry chloramine-T powder or chloramine 
T bonded to polymer beads, with a solution of a 
secondary amine to reduce the oxidation potential 
of chloramine-T, to form a mixture, 
(b) shaking said mixture until all the chloramine-T 
powder of chloramine-T bonded to polymer beads 
has dissolved, 
(0) adding a solution of KI* or NaI* to said mixture of 
step (b), wherein 1* represents a radioisotope of 
iodine, 
(d) shaking said mixture of step (c) for a time suffi 
cient to release If in solution, 
(e) adding a solution of a biomolecule substrate to 
said mixture of step (d), 
(f) shaking the resulting mixture of step (e) until thev 
brown color disappears, and 
(g) recovering the radioiodinated biomolecule. 
10. The method of claim 9, wherein said secondary 
amine is piperidine (PIP) buffered at about pH 6.0 in 
molar excess over chloramine-T powder. 
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11. The method of claim 9, wherein dry chloramine 
T powder is mixed with the said secondary amine in 
step (a). 
12. The method of claim 9, wherein chloramine-T 
bonded to polymer beads is mixed with said secondary 
amine in step (a). 
13. The method of claim 9, wherein said secondary 
amine is selected from dialkyl amines. 
14. The method of claim 9, wherein said secondary 
amine is selected from the group consisting of diisopro 
pylamine, dibutylamine and piperidine (PIP). 
15. The method of claim 9, wherein said time suf? 
cient to release 12* in solution is about 30 seconds. 
16. A kit for non-destructively radiolabelling bi 
omolecules by halogenation, comprising 
(a) a vial comprising a chlorinating agent, 
(b) a vial comprising a solution of a secondary amine, 
(c) a vial comprising a solution of a salt of a radi 
olabelled halogen, and 
(d) instructions for use. 
17. The kit of claim 16, wherein said secondary amine 
is selected from dialkylamines. 
18. The kit of claim 16, wherein said secondary amine 
is selected from the group consisting of diisopropyl 
amine, dibutylamine and piperidine (PIP). 
19. A method of non-destructively radiolabelling a 
biomolecule substrate by halogenation, comprising the 
steps of: 
(a) mixing dry chloramine-T powder or chloramine 
T bonded to polymer beads, with a solution of a 
secondary amine in molar excess over said chlora 
mine-T powder or chloramine-T bonded to poly 
mer beads, to form ‘a mixture, 
(b) shaking said mixture until all the chloramine-T 
powder or chloramine-T bonded to polymer beads 
has dissolved, 
(c) adding a solution of KX* or NaX* to said mixture 
of step (b), wherein X* is a radioisotope of a halo 
gen: 
(d) shaking said mixture of step (c) for ‘a time suffi 
cient to release X* in solution, 
(e) adding a solution of a biomolecule substrate to 
said mixture of step (d), 
(f) shaking the resulting mixture of step (e) until the 
color disappears, and 
(g) recovering the radiohalogenated biomolecule. 
20. The method of claim 19, wherein X* is selected 
from the group consisting of radioactive iodide or bro 
mide. 
21. The method of claim 20, wherein said radioactive 
iodide is selected from the group consisting of 121I, 1351 
and said radioactive bromide is 77Br. 
22. The method of claim 20, wherein X* is radioac 
tive iodide. 
